Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $21.2M | $31.6M | $46.3M | $59.3M | $67.4M | $72.0M | $83.6M | $99.6M | $129M |
| Revenue growth | — | — | 48.8% | 46.7% | 28.0% | 13.8% | 6.8% | 16.0% | 19.2% | 29.9% |
| Gross profit | $7.53M | $10.5M | $16.1M | $25.8M | $35.3M | $41.5M | $42.8M | $50.8M | $61.6M | $83.2M |
| Gross margin | — | 49.4% | 50.9% | 55.7% | 59.5% | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating income | -$2.07M | -$16.4M | -$33.2M | -$31.3M | -$19.9M | -$27.1M | -$18.6M | -$5.60M | $7.73M | $16.3M |
| Operating margin | — | -77.2% | -105.1% | -67.6% | -33.5% | -40.1% | -25.9% | -6.7% | 7.8% | 12.6% |
| Net income | -$2.77M | -$11.4M | -$33.3M | -$32.1M | -$19.9M | -$27.1M | -$16.5M | -$4.94M | $8.55M | $17.4M |
| Net margin | — | -53.7% | -105.6% | -69.4% | -33.6% | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% |
| EPS (diluted) | -$0.08 | -$0.26 | -$0.61 | -$0.56 | -$0.33 | -$0.40 | -$0.24 | -$0.07 | $0.11 | $0.20 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.11M | -$9.80M | -$20.9M | -$20.4M | -$10.6M | -$24.2M | -$15.1M | $7.12M | $12.1M | $13.5M |
| Capital expenditures | $525K | $1.17M | $1.32M | $743K | — | — | — | — | — | — |
| Free cash flow | -$2.64M | -$11.0M | -$22.2M | -$21.2M | — | — | — | — | — | — |
| Share buybacks | — | $0.00 | $404K | — | — | — | — | — | $0.00 | $251K |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $22.6M | $18.8M | $16.7M | $28.2M | $20.4M | $27.3M | $44.7M | $64.8M |
| Total assets | $19.8M | $62.7M | $42.2M | $40.2M | $38.4M | $57.8M | $54.1M | $55.0M | $68.3M | $106M |
| Total liabilities | $9.78M | $8.89M | $15.1M | $19.8M | $21.9M | $26.1M | $25.4M | $26.5M | $22.2M | $29.9M |
| Long-term debt | $3.35M | — | — | — | — | — | — | — | — | — |
| Shareholders' equity | $9.97M | $53.8M | $27.2M | $20.4M | $16.4M | $31.7M | $28.7M | $28.5M | $46.1M | $76.5M |
| Retained earnings | -$45.2M | -$56.6M | -$89.8M | -$122M | -$142M | -$169M | -$185M | -$190M | -$182M | -$165M |
| Shares (wtd avg diluted) | 35.9M | 54.7M | 55.1B | 59.6M | 61.1M | 67.2M | 69.7M | 75.0M | 78.1M | 85.4M |
Every figure is extracted from Niagen Bioscience, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.